Dupilumab-Associated Vitiligo: Research finds Early Recognition, Nemolizumab and Targeted Topical Therapy is the key
A new study published in the journal of Cureus showed that vitiligo may occur as a rare adverse effect of dupilumab therapy in patients with atopic dermatitis (AD). Early recognition is important to reconsider biologic therapy and initiate appropriate topical treatment. Topical JAK-STAT inhibition may potentially offer greater repigmentation than calcineurin inhibition, but this remains an unproven hypothesis based on a single case. Larger, prospective controlled studies are needed to confirm treatment efficacy and clarify the underlying immunologic mechanisms.
The treatment of moderate-to-severe atopic dermatitis has been transformed by dupilumab, a monoclonal antibody that targets the IL-4 and IL-13 pathways. However, new data points to uncommon immune-mediated side effects, such as the start or worsening of vitiligo. Potential immunological dysregulation and cytokine imbalance after IL-4/IL-13 suppression are part of the pathophysiology.
This study provides a case report of a 57-year-old lady with long-term atopic dermatitis (AD) who acquired new-onset vitiligo after receiving dupilumab medication in order to document a case of dupilumab-induced vitiligo in a patient with AD and assess the therapeutic options for management. After that, the patient was treated with topical tacrolimus 0.1% ointment on one hand and ruxolitinib cream on the other to evaluate the effectiveness of the two treatments. Nemolizumab is an IL-31 receptor antagonist. The patient was then transferred to nemolizumab, an IL-31 receptor antagonist, and given topical tacrolimus 0.1% ointment on one hand and ruxolitinib cream on the other to compare therapy effectiveness.
3 months after starting dupilumab, the patient developed depigmented patches on both metacarpophalangeal joints, which were consistent with non-segmental vitiligo. There was no prior history of vitiligo or autoimmune illness. Within 8 weeks of starting nemolizumab and topical therapies, there was a considerable improvement. The hand treated with ruxolitinib showed better repigmentation than the tacrolimus-treated hand. This instance demonstrates dupilumab's ability to cause vitiligo via Th2 cytokine suppression and subsequent Th1/Th17 activation, resulting in melanocyte death.
Overall, the significance of clinical knowledge about vitiligo as a possible side effect of dupilumab treatment in atopic dermatitis patients is highlighted by this example. Early detection of this issue enables physicians to rapidly explore focused topical therapy and reevaluate biologic selection, perhaps improving patient outcomes.
Although this observation is limited by the single-patient design and baseline asymmetry between treated sites, this experience suggests that topical JAK-STAT inhibition may provide a repigmentation benefit over calcineurin inhibition in this setting. However, this observation should not be interpreted as proving therapeutic superiority.
Source:
Colon, J., & Falabella, A. (2026). Dupilumab-induced vitiligo managed effectively with nemolizumab and targeted topical therapy. Cureus, 18(7), e113228. https://doi.org/10.7759/cureus.113228
